EMA Set To Adopt Safe-Use Recommendations For Anti-Epilepsy Drug Valproate

The European Medicines Agency is scheduled to adopt final recommendations for improving the safety of the anti-epileptic drug valproate – the subject of the agency’s very first public hearing.

Microphones
Valproate was the subject of the EMA's first ever public hearing • Source: Shutterstock

The European Medicines Agency's pharmacovigilance committee (PRAC), which is meeting this week, is expected to adopt final recommendations on the anti-epileptic drug, valproate, to address ongoing concerns with its use in women and girls who are pregnant or of childbearing age.

The drug, originally from Sanofi but now widely available as a generic, was the subject of PRAC's first ever public...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet